Dezhan Healthcare Co Ltd

Dezhan Healthcare maintains a strong liquidity position, as evidenced by a current ratio of 34.87, indicating that the company has significantly more current assets than current liabilities. However, the company reported negative operating cash flow of -10,283,660 CNY and capital expenditures of -39,373,030 CNY, which may signal ongoing investment in long-term assets or operational challenges. The price-to-book ratio of 1.31 and the price-to-tangible-book ratio of 1.31 suggest that the company's market value is slightly above its book value, indicating a moderate level of investor confidence in the company's intangible assets.

In terms of profitability, Dezhan Healthcare's return on equity (ROE) of 0.0051 and return on assets (ROA) of 0.005 are relatively low, suggesting that the company is not generating substantial returns relative to its equity and asset base. The company's gross profit margin is 65.17% (95,848,520 CNY / 147,067,190 CNY), which is a strong indicator of cost control and pricing power. However, the operating margin of 15.97% (23,482,000 CNY / 147,067,190 CNY) is lower, indicating that operating expenses are consuming a significant portion of gross profit.

Dezhan Healthcare's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. The company's geographic exposure is not specified, but the absence of segmental or geographic diversification may increase its vulnerability to regional economic or regulatory changes.

The company's growth trajectory is not clearly defined in the available data. The outlook for the current fiscal year and the next fiscal year is not provided, and there are no numeric deltas to indicate expected revenue growth or decline. The company's historical revenue of 147,067,190 CNY provides a baseline, but without forward-looking guidance, it is difficult to assess the company's growth potential.

Dezhan Healthcare faces several risk factors, including a medium liquidity risk due to negative operating cash flow and capital expenditures. The company's debt-to-equity ratio of 0.0 indicates that it is not leveraging debt to finance its operations, which is a positive sign. However, the risk assessment notes that net cash is negative after subtracting total debt, which could be a concern if the company's cash flow does not improve. The dilution risk is assessed as low, and there are no adjustments applied to the valuation metrics, suggesting that the company's capital structure is stable.

Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The absence of recent transcripts or filings may indicate a lack of transparency or public communication from the company. The ESG score of 13.38 and the ESG grade of D suggest that the company has significant room for improvement in environmental, social, and governance practices.

Dezhan Health Care Co Ltd (000813.SZ) has undergone a significant update to its corporate taxonomy, with its primary activity now explicitly classified as "Pharmaceuticals" and its economic sector identified as "Healthcare." This structural clarification, marked as a medium-severity change, establishes the foundational context for analyzing the company's operational focus and market positioning within the broader healthcare industry. Concurrently, the company's risk profile has been formally assessed, introducing new metrics for dilution and liquidity. The dilution risk is currently rated as "low," suggesting that existing shareholders face minimal immediate threat from equity expansion. This assessment provides a baseline for evaluating capital structure stability, although the absence of specific officer or analyst coverage data limits the depth of external validation for these internal risk classifications. In contrast to the low dilution risk, the company's liquidity risk has been categorized as "medium." This distinction highlights a potential area of financial friction that warrants monitoring, as it may impact the firm's ability to meet short-term obligations or fund operations without additional capital raising. The divergence between low dilution risk and medium liquidity risk suggests a capital structure that is stable in terms of ownership but requires careful management of cash flow and asset conversion. These updates collectively refine the investment thesis for Dezhan Health Care by anchoring its identity in the pharmaceutical sector while flagging specific financial risks. With no current analyst estimates or index memberships recorded, the significance of these new risk and taxonomy fields lies in their role as primary indicators for investors assessing the company's fundamental health and sector alignment. The lack of top holder data further underscores the need for reliance on these newly established risk metrics for due diligence.

Operating and net margins exceed the 75th percentile of the pharmaceutical cohort, indicating superior profitability relative to peers.

The company maintains a zero debt-to-equity ratio, significantly outperforming the cohort median of 0.18 and minimizing leverage risk.

Low dilution and credit risk flags suggest a stable capital structure with minimal threat to shareholder value from financing issues.

Cash conversion ratio sits in the bottom quartile of the cohort, highlighting poor ability to translate earnings into cash.

Revenue ¥119.3M, +6,5% YoY; Operating income −707,3% YoY.

• ▍Revenue ¥119.3M, +6,5% YoY
• ▍Operating income −707,3% YoY
• ▍Net income −897,8% YoY
• ▍Net margin -238.4%

Revenue ¥89.3M; Operating income -¥25.7M.

• ▍Revenue ¥89.3M
• ▍Operating income -¥25.7M
• ▍Net margin -24.8%

Revenue ¥112.0M; Operating income -¥42.5M.

• ▍Revenue ¥112.0M
• ▍Operating income -¥42.5M
• ▍Net margin -25.4%

Revenue ¥106.2M; Operating income -¥6.8M.

• ▍Revenue ¥106.2M
• ▍Operating income -¥6.8M
• ▍Net margin -1.9%

Revenue ¥147.1M; Operating income ¥23.5M.

• ▍Revenue ¥147.1M
• ▍Operating income ¥23.5M
• ▍Net margin 18.3%

Revenue ¥466.5M, −6,3% YoY; Operating income −155,5% YoY.

• ▍Revenue ¥466.5M, −6,3% YoY
• ▍Operating income −155,5% YoY
• ▍Net income −124,5% YoY
• ▍Free cash flow −469,8% YoY
• ▍Net margin -4.4%

Revenue ¥498.1M, −12,8% YoY; Operating income +165,5% YoY.

• ▍Revenue ¥498.1M, −12,8% YoY
• ▍Operating income +165,5% YoY
• ▍Net income +277,6% YoY
• ▍Free cash flow +82,7% YoY
• ▍Net margin 16.7%

Revenue ¥734.5M; Operating income -¥37.2M.

• ▍Revenue ¥734.5M
• ▍Operating income -¥37.2M
• ▍Net margin -7.8%